GleamWall
中文EN

AVCRF Avricore Health Inc. IFRS

Pharmaceutical Preparations · OTC · SEC CIK 1355736 · Reporting currency CAD · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY33.7%
TTM net income YoY4.6%
TTM EPS YoY0.0%
Revenue 3-yr CAGR236.0%
Net income 3-yr CAGR—

Margins

Gross margin40.4%
Operating margin—
Net margin-14.4%
FCF margin17.7%
EBITDA margin—

Returns

ROE-33.6%
ROA-27.7%
ROIC (approx.)—
Asset turnover1.93x

Leverage & solvency

Liabilities / assets14.4%
Debt / equity0.00x
Current ratio—
Interest coverage—

Cash quality & payout

Operating cash flow / net income-1.50x
Accruals ratio-69.2%
Payout ratio—
Capex / revenue3.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: CAD 2023Q4*2023-12-312023Q3*2023-09-302023Q2*2023-06-302022Q4*2022-12-312022Q3*2022-09-302022Q2*2022-06-30
Income statement
Revenue1.35M953,454522,156977,235572,228176,175
Cost of revenue852,937691,676318,578808,390356,267119,301
Gross profit501,466261,778229,471168,845215,96156,874
SG&A expense73,21179,720101,78058,80984,43473,032
Net income59,584-285,062-284,225-244,789-180,398-207,363
EPS (basic)—0.000.00—0.000.00
EPS (diluted)—0.000.00—0.000.00
Weighted avg. shares (diluted)—99.64M99.63M—97.70M97.70M
Balance sheet
Cash & equivalents276,571389,531472,371620,527869,1291.44M
Receivables427,689461,147213,513770,373——
Inventory20,676—————
Current assets773,561916,978754,6421.43M——
PP&E, netmay include right-of-use assets (IFRS)1.72M1.50M1.36M1.11M——
Intangibles—32,45933,82929,861——
Total assets2.54M2.45M2.14M2.57M——
Current liabilities—646,498356,438604,893——
Total liabilities529,218646,498356,438604,893——
Shareholders' equity2.01M1.81M1.79M1.96M1.75M1.86M
Cash flow statement
Operating cash flow248,003184,568—-24,27219,821—
Capital expenditure343,326267,241—429,210607,759—
Free cash flow-95,323-82,673—-453,482-587,938—
Investing cash flow-360,963-267,408—-439,210-610,193—
Financing cash flow00—214,88015,000—
Depreciation & amortization587667781-104,38675,37322,065
Stock-based compensation142,765304,328168,518243,00058,3549,069

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.